List view / Grid view

sarcoma

 

news

FDA grants Priority Review for olaratumab BLA

4 May 2016 | By Victoria White, Digital Content Producer

The US Food and Drug Administration (FDA) has granted Priority Review to Lilly’s biologics license application (BLA) for olaratumab, in combination with doxorubicin, for the potential treatment of people with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery.